Clinical Trials Logo

Filter by:
NCT ID: NCT01853254 Completed - Clinical trials for Hepatitis C, Chronic

A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

Start date: September 2003
Phase: Phase 3
Study type: Interventional

This open-label, non-randomized, single arm study will provide treatment or re-treatment with Pegasys (peginterferon alfa-2a) as monotherapy or in combination with Copegus (ribavirin) to patients with chronic hepatitis C infection. Patients who have received prior Pegasys monotherapy or combination therapy or who were considered eligible for treatment with Pegasys in previous donor protocols will be eligible to participate in this study. Treatment will be on investigator's decision according to the approved label for up to 48 weeks, with a 24-week safety follow-up.

NCT ID: NCT01852552 Completed - Clinical trials for Aortic Valve Stenosis

Costs, Cognitive Abilities and Quality of Life After Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement

CCQ
Start date: December 2011
Phase: N/A
Study type: Observational [Patient Registry]

Multicenter, prospective, observational study in aortic stenosis (AS) patients undergoing transcatheter aortic valve implantation (TAVI) or high-risk patients undergoing aortic valve replacement (AVR). The objectives of the study are: 1. Description of neurocognitive status before and after transcatheter aortic valve implantation and aortic valve replacement procedures 2. Description of Quality of Life (QoL) after these procedures 3. Defining the relevance of baseline psychological, emotional and cognitive factors on the outcomes associated to the different treatment modalities 4. Assessment of costs associated to each of the above mentioned strategies of treatment, including costs of the index hospitalization and costs of follow-up.

NCT ID: NCT01852500 Completed - Prematurity Clinical Trials

Are Newborns Conscious of the Placebo Effect? Result From an RCT in Osteopathy

Start date: November 2010
Phase: Phase 4
Study type: Interventional

Results from previous studies suggest the association between Osteopathic Manipulative Treatment (OMT) and length of stay (LOS) reduction in a population of preterm infants. The primary objective of the present study is to evaluate the effectiveness of sham OMT in reducing LOS in a sample of preterm newborns, in order to investigate whether previous clinical results could be related to a hypothetical placebo effect.

NCT ID: NCT01852058 Completed - Clinical trials for Urinary Incontinence

A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity

Start date: January 11, 2014
Phase: Phase 3
Study type: Interventional

This study will evaluate the long-term safety and efficacy of onabotulinumtoxinA (botulinum toxin Type A; BOTOX®) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in participants who successfully completed Study 191622-120 (NCT01852045).

NCT ID: NCT01852045 Completed - Clinical trials for Urinary Incontinence

Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients

Start date: July 2, 2013
Phase: Phase 3
Study type: Interventional

This study will evaluate the 3 doses of onabotulinumtoxinA (botulinum toxin Type A) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in pediatric participants between the ages of 5 to 17 years to determine if 1 or more doses were safe and effective.

NCT ID: NCT01851304 Completed - Obesity Clinical Trials

Metabolic Effect of New Foods Through Gut-brain Axis

CHECKMATE
Start date: September 2014
Phase: N/A
Study type: Interventional

A diet high in easily obtained energy-dense foods leads to the problems of overweight and obesity common in the developed world. Foods enriched with fiber or bitter compounds may increase satiety and decrease energy intake. This intervention will measure the effectiveness of coffee melanoidins, bread melanoidins, beta-glucans, and a Gentiana lutea L. extract in both a free or encapsulated form to decrease energy intake and modify the physiological markers of satiety in the short term. In particular bread (fiber) and a pudding (Gentiana lutea L. extract) will be used as tasty food matrices in the study.

NCT ID: NCT01851200 Completed - Germ Cell Cancer Clinical Trials

Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors

Start date: May 2013
Phase: Phase 2
Study type: Interventional

The purpose of the study is to assess the activity of Brentuximab vedotin in refractory germ cell tumors.

NCT ID: NCT01851148 Completed - Migraine Clinical Trials

Clinical Effectiveness of Osteopathic Manipulative Treatment in Chronic Migraine

Start date: March 2010
Phase: N/A
Study type: Interventional

The aim of the present study is to determine the extend to which OMT is effective on a sample of subjects affected by migraine evaluated using the headache impact test (HIT-6) questionnaire.

NCT ID: NCT01850212 Completed - HIV Infections Clinical Trials

A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects

Start date: February 2013
Phase: Phase 4
Study type: Observational

A Phase 4 study is to characterize the profile of low bone mineral density (BMD) in ≥ 50 year old male subjects and post-menopausal female subjects on any tenofovir disoproxil fumarate (TDF)-based regimen

NCT ID: NCT01850004 Completed - Clinical trials for Chronic Phase Chronic Myeloid Leukemia

Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response

DASFREE
Start date: January 22, 2014
Phase: Phase 2
Study type: Interventional

The study purpose is to test the hypothesis that Chronic Phase Chronic Myeloid Leukemia (CP-CML) patients with stable Complete Molecular Response (CMR) who discontinue Dasatinib treatment are able to maintain a sustained remission in the long-term, with undetectable or minimally detectable BCR-ABL residual disease.